Novartis Zometa 8 Mg HCM Retreatment Dose Would Need New Study – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Approval of an 8 mg Zometa dose for retreatment of patients with hypercalcemia of malignancy (HCM) would require a new study as well as additional safety data, FDA said in its Aug. 20 approval letter for a 4 mg dose of Novartis’ zoledronic acid
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class